Abstract: A slurry distributing device including a roller conveyer having a series of roller sections, each section driven by a respective motor and employing a combination of direct drive and belt drive. The slurry distributing device is used for the uniform and low-speed flow distribution of slurries. The invention also relates to a conveyor line for the continuous production of gypsum drywall boards employing the slurry distributing device. The invention also relates to a method for the continuous production of gypsum drywall boards employing the slurry distributing device.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.

Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: Some embodiments are directed to a container for dispensing a flowable solid (e.g., powder) that comprises an interior volume and a partition separating the interior volume into a storage volume and a passage. The passage may include a dosing chamber and a passage. The storage volume may be in direct communication with the dosing chamber. The storage volume may include a floor positioned above the dosing chamber. The outlet passage may extend from the dosing chamber to an outlet. The partition may extend below the floor of the storage volume such that the partition restricts the flow of the flowable solid from the storage volume when the container is at least partially inverted to dispense a dose of flowable solid each time the container is at least partially inverted. The container may consistently dispense equal doses of flowable solid regardless the amount of flowable solid remaining in the storage volume.

Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: Computerized methods are disclosed for automated question generation from source documents through natural language processing, for applications including training and testing. Interleaved selection and transformation phases employ combined semantic-syntactic analysis to progressively refine natural input text into a high density of text fragments having high content value. Non-local semantic content and attributes such as emphasis attributes can be attached to the text fragments. The text fragments are reverse parsed by matching against a precomputed library of combined semantic-syntactic patterns. Once the patterns of each fragment are determined, transformation of fragments into question-answer pairs is performed using question selectors and answer selectors tailored to each pattern. Methods for constructing distractors, both internal and external, are also disclosed. The ecosystem of machine learning components, ontology resources, and process improvement are also described.

Abstract: Architectures and techniques to visually indicate an operational state of an electronic device. In some instances, the electronic device comprises a voice-controlled device configured to interact with a user through voice input and visual output. The voice-controlled device may be positioned in a home environment, such as on a table in a room of the environment. The user may interact with the voice-controlled device through speech and the voice-controlled device may perform operations requested by the speech. As the voice-controlled device enters different operational states while interacting with the user, one or more lights of the voice-controlled device may be illuminated to indicate the different operational states.

Abstract: A hydrocarbon fluid pipeline may include pipeline segments connected together in end-to-end relation between first and second spaced apart geographic locations and configured to carry hydrocarbon fluid therethrough. The hydrocarbon fluid pipeline may also include a radio frequency (RF) heating station that may include an RF source and an RF heater between adjacent pipeline segments of the plurality thereof. The RF heater may include an inner tubular dielectric coupler between the adjacent pipeline segments, and an electrically conductive outer housing surrounding the inner tubular dielectric coupler and connected to the RF source to heat the hydrocarbon fluid.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: Techniques involving modeling and analysis of operational metrics in transportation industries are disclosed. Representative methods involve defining a set of fuel consumption performance factors having a potential to impact vehicle fuel economy. Fuel consumption performance factors are received, and categorical variables are identified from at least a subset of the fuel consumption performance factors to create one or more categorical groupings. The fuel consumption performance factors associated with at least one of the categorical groupings are processed to identify a hypothetical maximum fuel economy or “baseline” for the at least one of the categorical groupings, and to identify fuel economy deduction coefficients based on the fuel consumption performance factors that adversely impact the hypothetical maximum fuel economy.

Abstract: An extendable speaker system is provided with a base and lid that are connected via a plurality of concentric collapsible hollow bodies such as cylinders. A woofer speaker resides in the base. Mid range or tweeter speakers reside in the lid. The lid is displaced away from the base to expand the speaker system, where the extended cylinders provide an airtight seal between the base and lid forming a woofer speaker enclosure therein. Friction seals between the cylinders, a spring residing within the speaker enclosure, and the airtight speaker enclosure itself provide a collective force sufficient to maintain the speaker system in an extended configuration. A port is opened by depressing a button to vent the enclosure to allow for the speaker system to be collapsed. A locking system is provided to releasably maintain the speaker system in a collapsed configuration.